RxDoctor Payments Data

Vincent Demarco, DO

Family Medicine · Blue Springs, MONPI 1942649538

Payments from drug & device makers

$9,960in general payments, 2019–2025

Across 390 payments — averaging $25.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Valeritas, Inc.$4K
  • AbbVie$798
  • Novo Nordisk$630
  • Lilly USA, LLC$465
  • Boehringer Ingelheim$457
  • AstraZeneca$457
  • plus $3K from 47 others

What the payments were for

  • Speaking & faculty fees$3,60036%
  • Food & beverage$6,36064%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,960 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$149,059
Medicare patients
313
Services billed
1,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$151,290
JardianceEmpagliflozin96$82,644
FarxigaDapagliflozin Propanediol49$67,402
TrulicityDulaglutide39$66,365
EliquisApixaban38$43,651
MounjaroTirzepatide27$36,306
Repatha SureclickEvolocumab27$22,636
ArexvyRsvpref3 Antigen/As01e/Pf80$21,470
V-Go 20Sub-Q Insulin Device, 20 Unit33$19,515
JanuviaSitagliptin Phosphate12$17,515
V-Go 30Sub-Q Insulin Device, 30 Unit19$16,973
XareltoRivaroxaban14$14,382
VascepaIcosapent Ethyl16$14,106
Tresiba Flextouch U-200Insulin Degludec14$11,977
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$11,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$630$151,29094 claims
Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro$465$104,930101 claims
Boehringer IngelheimJardiance$457$82,64496 claims
AstraZenecaFarxiga, Bevespi Aerosphere$457$72,92660 claims
PfizerEliquis$362$43,65138 claims
GSKArexvy, Breo Ellipta$215$30,97291 claims
MerckJanuvia$98$17,51512 claims
Johnson & JohnsonXarelto$54$14,38214 claims
AbbVieSynthroid$798$1,35123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Blue Springs

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →